<DOC>
	<DOC>NCT00902265</DOC>
	<brief_summary>Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (Nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.</brief_summary>
	<brief_title>Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Polyuria</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Therapeutic need according to Summary of Product Characteristics Written informed consent Contraindications according to Summary of Product Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>